Waters Corporation

WAT · NYSE · ·

Vergelijken

US$ 460,23-0,4%slot 13 nov

Cijfers tot en met 3 oktober 2026, uit de 10-Q ingediend op 10 november 2026

1W: +0,6%
1M: +5,4%

Just reported

Q3 2026 results

From Waters's results release of 3 november 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,77B
+121% y/y
+7,4% q/q
Guided
US$ 858,5M
midpoint
Above guide+106%
EPS, GAAP
Actual
US$ 0,82
-67% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 128M
-33% y/y
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$ 3,429B+8,3% y/y Raised +1,8%
EPS, adjustedUS$ 14,60 – US$ 14,70Raised +1,4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Waters is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Samengesteld
Lab tools & diagnostics
Door InspectStocks · 20 companies
Instruments, supplies and testing services for labs, drugmakers and doctors.
Koers, 1 jaar
+22,4%
Omzet, 1 jaar
+7,8%
+14
A 8B 8C 2D 1F 1

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Volledige jaarrekening →

Gebouwd uit de eigen deponeringen van Waters Corporation bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.

Waters Corporation

Waters Corporation

Q3 2026 results

Revenue

EPS, GAAP